- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04132388
Hidradenitis Suppurativa Patient Experience With Humira Treatment
Hidradenitis Suppurativa Patients' Experience of Treatment With Adalimumab
Hidradenitis suppurativa (HS) is a chronic relapsing condition with significant psychosocial impact and morbidity, but that doesn't mean that patients will necessarily be adherent to recommended treatments. Patients, especially those on chronic medication therapy, inevitably miss doses. They use too little or too much therapy. They may take medications too soon or too far apart. While adherence to injection treatments tend to be better than adherence to topical or oral treatment, adherence to injections may still be poor.
Traditional methods for measuring medical adherence-including questionnaires, surveys, and diaries- tend to be unreliable overestimate adherence. Chemical markers are problematic because of the tendency for patients to use their medication right before visits, so called "white coat compliance." Our research team has pioneered the use of electronic monitoring devices which measure and record the date and time of medication events to assess adherence in dermatology. The study team have demonstrated the feasibility of using such monitors to measure adherence to adalimumab in patients with psoriasis. Although only a small study, it documented a broad range of how patients use adalimumab and found that adherence was poor in about half of the patients. While the impact of psoriasis on patients' lives is large, adherence is still poor. How adherent patients with hidradenitis are to weekly adalimumab treatment is not yet well characterized.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective single-center open-label randomized 6 month study. There will not be a washout period. Treatment will be for 26 weeks.
Subjects will have baseline disease severity assessments. Subjects will be instructed to take adalimumab according to the labelled dosing regimen. Subjects will be randomized to either standard-of-care or to an electronic reporting intervention.
The reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.
Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit.
Primary Endpoints: Adherence to adalimumab treatment
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27104
- Wake Forest Health Sciences Dermatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects ages 18 - 70
- Diagnosis of HS for which adalimumab is indicated according to the adalimumab prescribing information.
- All subjects must have a negative TB skin test according to prescribing guidelines.
- Subjects must be starting adalimumab for the first time, prescribed by their dermatologist.
Exclusion Criteria:
- All experimental drugs or devices are to be discontinued at least 1 month prior to initiation of study therapy.
- Subjects who are receiving biologic therapy with a potential therapeutic impact on hidradenitis within 3 months will be excluded.
- Pregnant and nursing females will not be allowed in the study, and females of childbearing potential will have a pregnancy test at baseline. Females of childbearing potential must agree to use approved birth control methods for the duration of the study.
- Subjects who have received live vaccines within a 3 month period prior to enrollment will also be excluded.
- In addition, subjects who have any skin condition or disease that may require concurrent therapy or may confound the evaluation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard-of-Care
Subjects will be instructed to take adalimumab according to the labeled dosing regimen.
Subjects will return for evaluation at 12 & 26 weeks (or end of study).
At each visit the subject will be scored for disease severity and adverse events.
The assessor of these measures will be blinded to treatment group assignment.
At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey.
Pregnancy tests will be completed on females of childbearing potential at the baseline visit.
|
Subjects will be instructed to take Humira according to the labelled dosing regimen.
Treatment will be for 26 weeks
Other Names:
|
Experimental: Electronic Reporting
Subjects will be instructed to take adalimumab according to the labeled dosing regimen. The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter. Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit. |
Subjects will be instructed to take Humira according to the labelled dosing regimen.
Treatment will be for 26 weeks
Other Names:
The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter. Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of days between each dose for all subjects
Time Frame: week 12 post randomization
|
assessment of adalimumab treatment
|
week 12 post randomization
|
Number of days between each dose for all subjects
Time Frame: week 26 post randomization
|
assessment of adalimumab treatment
|
week 26 post randomization
|
Percentage of patients who achieve adherence success
Time Frame: week 12 post randomization
|
percentage who have taken over 90% of correct doses of study drug
|
week 12 post randomization
|
Percentage of patients who achieve adherence success
Time Frame: week 26 post randomization
|
percentage who have taken over 90% of correct doses of study drug
|
week 26 post randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Doses Taken
Time Frame: week 12 post randomization
|
Measured by MEMs cap
|
week 12 post randomization
|
Number of Doses Taken
Time Frame: week 26 post randomization
|
Measured by MEMs cap
|
week 26 post randomization
|
Physician Global Assessment (PGA)
Time Frame: week 12 post randomization
|
Assessment score ranges from 0 to 5 with a higher score denoting a worse outcome.
|
week 12 post randomization
|
Physician Global Assessment (PGA)
Time Frame: week 26 post randomization
|
Assessment score ranges from 0 to 5 with a higher score denoting a worse outcome.
|
week 26 post randomization
|
Hidradentis Suppurativa Clinical Response (HiSCR)
Time Frame: week 12 post randomization
|
Hidradenitis Suppurativa Clinical Response (HiSCR) measures number of inflammatory lesions.
|
week 12 post randomization
|
Hidradentis Suppurativa Clinical Response (HiSCR)
Time Frame: week 26 post randomization
|
Hidradenitis Suppurativa Clinical Response (HiSCR) measures number of inflammatory lesions.
|
week 26 post randomization
|
Dermatology Life Quality Index (DLQI)
Time Frame: week 12 post randomization
|
Scale ranges from 0 to 30 with a higher rating denoting a worse outcome.
|
week 12 post randomization
|
Dermatology Life Quality Index (DLQI)
Time Frame: week 26 post randomization
|
Scale ranges from 0 to 30 with a higher rating denoting a worse outcome.
|
week 26 post randomization
|
Number of Doses Missed
Time Frame: week 26 post randomization
|
week 26 post randomization
|
|
Total Time in Study
Time Frame: week 26 post randomization
|
week 26 post randomization
|
Collaborators and Investigators
Investigators
- Principal Investigator: Rita O Pichardo, MD, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00050544
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hidradenitis Suppurativa
-
Yale UniversityNot yet recruitingHidradenitis Suppurativa | Hidradenitis Suppurativa, Acne Inversa | Hidradenitis Suppurativa \(HS\)United States
-
Boehringer IngelheimRecruiting
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Canada, Bulgaria, Italy, Spain, Germany, Poland, France, Australia, Denmark, United Kingdom
-
Novartis PharmaceuticalsAvailableHidradenitis Suppurativa (HS)
-
AbbVie (prior sponsor, Abbott)CompletedHidradenitis Suppurativa (HS)
-
InflaRx GmbHQuintiles, Inc.CompletedHidradenitis Suppurativa (HS)United States, Bulgaria, Canada, Denmark, France, Germany, Greece, Netherlands, Poland
-
Erasmus Medical CenterNot yet recruitingHidradenitis Suppurativa, Acne Inversa
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Canada, Czechia, Spain, Germany, Poland, Netherlands, Belgium, France, Greece, Japan, Austria
-
Wake Forest University Health SciencesActive, not recruiting
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Austria, Belgium, Canada, Germany, Poland, Spain, Australia, Denmark, France, United Kingdom, Japan, Bulgaria, Netherlands, Czechia, Greece, Italy
Clinical Trials on Adalimumab
-
PfizerCompletedHealthyUnited States, Belgium
-
PfizerCompletedHealthy SubjectsUnited States
-
AbbottCompletedArthritis, Juvenile IdiopathicUnited States, Belgium, Czech Republic, France, Germany, Italy, Slovakia, Spain
-
Shanghai Henlius BiotechCompleted
-
AbbottCompleted
-
Turgut İlaçları A.Ş.CompletedHealthy ParticipantsGermany
-
Mylan Inc.Mylan GmbHCompletedPsoriasis | Arthritis, PsoriaticBulgaria, Estonia, Hungary, Poland, Russian Federation, Ukraine
-
AbbottCompletedRheumatoid ArthritisSpain
-
SandozHexal AGCompletedPlaque Type PsoriasisUnited States, France, Bulgaria, Slovakia